Skip to main content
Fig. 2 | Cancer Communications

Fig. 2

From: First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

Fig. 2

Progression-free survival by mutation status: a a single common EGFR mutation vs. compound EGFR mutations (median PFS: 9.1 vs. 13.0 months, respectively; P < 0.001), b a single common EGFR mutation vs. common + T790M mutations (median: 9.1 months vs. 13.0 months, P < 0.001), c a single common EGFR mutation vs. common + rare mutations vs. rare + rare mutations vs. rare + T790M mutations (median: 13.0 months vs. 10.5 months vs. 6.5 months vs. 5.4 months, P = 0.006), and d a single EGFR mutation vs. compound mutations without exon 20 vs. compound mutations with exon 20 (median: 13.0 months vs. 9.1 months vs. 6.5 months, P = 0.002)

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us